Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001064231 - USE OF A COMPOSITION

Publication Number WO/2001/064231
Publication Date 07.09.2001
International Application No. PCT/SE2001/000447
International Filing Date 02.03.2001
Chapter 2 Demand Filed 17.09.2001
IPC
A61K 31/01 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
01Hydrocarbons
A61K 31/122 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/375 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
375Ascorbic acid, i.e. vitamin C; Salts thereof
CPC
A61K 31/01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
01Hydrocarbons
A61K 31/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
375Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 36/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
A61K 36/746
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
74Rubiaceae (Madder family)
746Morinda
Applicants
  • GIDLUND, Bo [SE]/[SE]
Inventors
  • GIDLUND, Bo
Agents
  • DR LUDWIG BRANN PATENTBYRÅ AB
Priority Data
0000698-102.03.2000SE
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF A COMPOSITION
(FR) UTILISATION D'UNE COMPOSITION
Abstract
(EN)
Use of an extract derived from the fruits, the leaves, the bark or the roots of Morinda citrifolia L. for the manufacture of a medicament for the treatment of a mammal suffering from tinnitus. The extract may be a liquid present in the medicament in an amount such as to give a daily dosage of 0.1-2 ml, or 0.2-1 ml, e.g. 0.4-0.7 ml, per kg body weight of the patient. The extract also may be a solid present in the medicament in an amount such as to give a daily dosage of 5-200 mg, or 10-100 mg, e.g. 20-70 mg, per kg body weight of the patient. Optionally, the medicament also may comprise lycopene, vitamine C, coenzyme Q10 and an extract from the leaves of Ginkgo biloba. The medicament may be given e.g. by oral, rectal, transdermal or inhalation administration.
(FR)
La présente invention concerne l'utilisation d'un extrait issu des fruits, des feuilles, de l'écorce ou des racines de Morinda citrifolia L. pour préparer un médicament utilisé dans le traitement d'un mammifère souffrant d'acouphène. L'extrait peut être un liquide qui se trouve dans le médicament suivant une quantité qui assure une posologie quotidienne comprise entre 0,1-2 ml, ou 0,2-1 ml, par exemple 0,4-0,7 ml, par kg de masse corporelle du patient. L'extrait peut être un solide qui se trouve dans le médicament suivant une quantité qui assure une posologie quotidienne comprise entre 5-200 mg, ou 10-100 mg, par exemple 20-70 mg, par kg de masse corporelle du patient. Le médicament peut facultativement comprendre également du lycopène, de la vitamine C, la coenzyme Q10 et un extrait provenant des feuilles de Ginkgo biloba. Le médicament peut être administré par exemple par voie orale, rectale, transdermique ou par inhalation.
Also published as
Latest bibliographic data on file with the International Bureau